The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells

Archives of Toxicology

Volumn 92, Issue 7, 2018, Pages 2227-2243

  Kiweler, Nicole ^a   Brill, Boris ^b   Wirth, Matthias ^c,d   Breuksch, Ines ^a   Laguna, Teresa ^e   Dietrich, Cornelia ^a   Strand, Susanne ^a   Schneider, Günter ^c   Groner, Bernd ^b   Butter, Falk ^e   Heinzel, Thorsten ^f   Brenner, Walburgis ^a   Krämer, Oliver H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e INSTITUTE OF MOLECULAR BIOLOGY IMB   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

EMT; HDAC1; HDAC2; HDACi; Proteomics; Renal cancer

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 9; CELL ADHESION MOLECULE; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; HISTONE H4; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TWIST RELATED PROTEIN 1; TWIST RELATED PROTEIN 2; UVOMORULIN; VALPROIC ACID; VIMENTIN; ZINC FINGER E BOX BINDING HOMEOBOX 2; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; KIDNEY METASTASIS; MRNA EXPRESSION LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; KIDNEY TUMOR; PATHOLOGY; RENAL CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; KIDNEY NEOPLASMS; MICE, INBRED BALB C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047661827     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-018-2229-5     Document Type: Article

References (59)

1. Beyer M, Kiweler N, Mahboobi S, Krämer OH (2017) How to distinguish between the activity of HDAC1-3 and HDAC6 with Western Blot. Methods Mol Biol 1510:355–364. 10.1007/978-1-4939-6527-4_26
2. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383–397. 10.1002/med.20027
3. Brabletz T (2012) To differentiate or not-routes towards metastasis. Nat Rev Cancer 12:425–436. 10.1038/nrc3265
4. Bradner JE et al (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 107:12617–12622. 10.1073/pnas.1006774107
5. Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116. 10.1007/s00441-011-1227-1
6. Cha TL et al (2009) Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15:840–850. 10.1158/1078-0432.ccr-08-1918
7. Christmann M, Kaina B (2013) Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res 41:8403–8420. 10.1093/nar/gkt635
8. Dejung M et al (2016) Quantitative proteomics uncovers novel factors involved in developmental differentiation of trypanosoma brucei. PLoS Pathog 12:e1005439. 10.1371/journal.ppat.1005439
9. Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23:257–258. 10.1093/bioinformatics/btl567
10. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673–691. 10.1038/nrd4360
11. Fischer KR et al (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472–476. 10.1038/nature15748
12. Fritzsche FR et al (2008) Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381–381. 10.1186/1471-2407-8-381
13. Giudice FS, Pinto DS Jr, Nor JE, Squarize CH, Castilho RM (2013) Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial–mesenchyme transition of head and neck cancer. PLoS One 8:e58672. 10.1371/journal.pone.0058672
14. Göttlicher M et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978. 10.1093/emboj/20.24.6969
15. Han HJ et al (2014) Suppression of E-cadherin mediates gallotannin induced apoptosis in Hep G2 hepatocellular carcinoma cells. Int J Biol Sci 10:490–499. 10.7150/ijbs.7495
16. Jiang GM et al (2013) Histone deacetylase inhibitor induction of epithelial–mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta 1833:663–671. 10.1016/j.bbamcr.2012.12.002
17. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA (2009a) The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13:2376–2385. 10.1111/j.1582-4934.2008.00436.x
18. Jones J et al (2009b) Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med 13:2342–2352. 10.1111/j.1582-4934.2008.00603.x
19. Juengel E et al (2011) Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha. World J Urol 29:779–786. 10.1007/s00345-010-0582-y
20. Juengel E et al (2014) HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Mol Cancer 13:152. 10.1186/1476-4598-13-152
21. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M (2008) Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 180:1131–1136. 10.1016/j.juro.2008.04.136
22. Keller SH, Nigam SK (2003) Biochemical processing of E-cadherin under cellular stress. Biochem Biophys Res Commun 307:215–223
23. Korfei M et al (2015) Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax 70:1022–1032. 10.1136/thoraxjnl-2014-206411
24. Lagger G et al (2002) Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21:2672–2681. 10.1093/emboj/21.11.2672
25. Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harbor Perspectives in Medicine 6 10.1101/cshperspect.a026831
26. Li Z, Zhu WG (2014) Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 10:757–770. 10.7150/ijbs.9067
27. Mahalingam D et al (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16:141–153. 10.1158/1078-0432.CCR-09-1385
28. Maurer-Gebhard M, Schmidt M, Azemar M, Stocklin E, Wels W, Groner B (1999) A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation. Hybridoma 18:69–75. 10.1089/hyb.1999.18.69
29. Meidhof S et al (2015) ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 7:831–847. 10.15252/emmm.201404396
30. Menegola E, Di Renzo F, Broccia ML, Prudenziati M, Minucci S, Massa V, Giavini E (2005) Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 74:392–398. 10.1002/bdrb.20053
31. Mikami S et al (2016) Recent advances in renal cell carcinoma from a pathological point of view. Pathol Int 66:481–490. 10.1111/pin.12433
32. Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) Emt: 2016. Cell 166:21–45. 10.1016/j.cell.2016.06.028
33. Nikolova T, Kiweler N, Krämer OH (2017) Interstrand crosslink repair as a target for HDAC inhibition. Trends Pharmacol Sci. 10.1016/j.tips.2017.05.009
34. Park KC et al (2015) The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells. BMC Cancer 15:19. 10.1186/s12885-014-1003-1
35. Pili R et al (2017) Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. Br J Cancer 116:874–883. 10.1038/bjc.2017.33
36. Piva F et al (2016) Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. Mol Diagn Ther 20:111–117. 10.1007/s40291-016-0192-5
37. Poreba M, Strozyk A, Salvesen GS, Drag M (2013) Caspase substrates and inhibitors. Cold Spring Harb Perspect Biol 5:a008680. 10.1101/cshperspect.a008680
38. Ramakrishnan S, Pili R (2013) Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J 19:333–340. 10.1097/PPO.0b013e3182a09e07
39. Rhodes LV et al (2014) Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 145:593–604. 10.1007/s10549-014-2979-6
40. Roy SS et al (2014) Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene 33:3707–3716. 10.1038/onc.2013.332
41. Ruscetti M et al (2016) HDAC inhibition impedes epithelial–mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 35:3781–3795. 10.1038/onc.2015.444
42. Schech A, Kazi A, Yu S, Shah P, Sabnis G (2015) Histone deacetylase Inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells. Mol Cancer Ther 14:1848–1857. 10.1158/1535-7163.mct-14-0778
43. Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol Adv Online Publ. 10.1038/nrclinonc.2017.44
44. Society AC (2017) Cancer Facts & Figs. 2017. https://old.cancer.org/acs/groups/content/@editorial/documents/document/acspc-048738.pdf. Accessed 13 June 2017
45. Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial–mesenchymal transition in vivo. Mol Cancer Ther 9:3254–3266. 10.1158/1535-7163.mct-10-0582
46. Tang HM et al (2016) An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discov 2:16041. 10.1038/cddiscovery.2016.41
47. Voon DC, Huang RY, Jackson RA, Thiery JP (2017) The EMT spectrum and therapeutic opportunities. Mol Oncol 11:878–891. 10.1002/1878-0261.12082
48. Wu S, Luo Z, Yu PJ, Xie H, He YW (2016a) Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol Chem 397:75–83. 10.1515/hsz-2015-0215
49. Wu Y, Lyu H, Liu H, Shi X, Song Y, Liu B (2016b) Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Sci Rep 6:31093. 10.1038/srep31093
50. Xu L, Tong R, Cochran DM, Jain RK (2005) Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65:5711–5719. 10.1158/0008-5472.CAN-04-4313
51. Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T (2013) A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol 43:1080–1086. 10.3892/ijo.2013.2042
52. Yao X, Ireland SK, Pham T, Temple B, Chen R, Raj MH, Biliran H (2014) TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherin. Biochem Biophys Res Commun 455:277–284. 10.1016/j.bbrc.2014.11.007
53. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH (2010) ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 29:1451–1462. 10.1038/onc.2009.433
54. Yoo CB, Yun SM, Jo C, Koh YH (2012) gamma-Secretase-dependent cleavage of E-cadherin by staurosporine in breast cancer cells. Cell Commun Adhes 19:11–16. 10.3109/15419061.2012.665969
55. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial–mesenchymal transitions. J Clin Investig 119:1429–1437. 10.1172/JCI36183
56. Zheng X et al (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525–530. 10.1038/nature16064
57. Zhou X et al (2014) Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma. Neoplasia 16:1028–1035. 10.1016/j.neo.2014.09.012
58. Zibelman M et al (2015) Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investig New Drugs 33:1040–1047
59. Zimmermann S et al (2007) Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Can Res 67:9047–9054. 10.1158/0008-5472.can-07-0312